Intellia Therapeutics (NTLA) Scheduled to Post Earnings on Thursday

Intellia Therapeutics (NASDAQ:NTLA - Get Free Report) will issue its quarterly earnings data before the market opens on Thursday, October 24th. Analysts expect the company to announce earnings of ($1.38) per share for the quarter. Parties that wish to register for the company's conference call can do so using this link.

Intellia Therapeutics (NASDAQ:NTLA - Get Free Report) last announced its earnings results on Thursday, August 8th. The company reported ($1.52) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($1.23) by ($0.29). The firm had revenue of $7.00 million during the quarter, compared to the consensus estimate of $19.68 million. During the same quarter in the previous year, the business earned ($1.40) earnings per share. The firm's revenue for the quarter was down 48.5% compared to the same quarter last year. On average, analysts expect Intellia Therapeutics to post $-5 EPS for the current fiscal year and $-5 EPS for the next fiscal year.

Intellia Therapeutics Stock Performance

Shares of NTLA stock traded up $0.40 on Thursday, reaching $20.98. 2,265,922 shares of the company's stock traded hands, compared to its average volume of 1,537,766. Intellia Therapeutics has a 12-month low of $17.09 and a 12-month high of $34.87. The company has a market capitalization of $2.02 billion, a P/E ratio of -3.84 and a beta of 1.76. The business's 50 day moving average price is $21.10 and its two-hundred day moving average price is $23.03.

Analysts Set New Price Targets

A number of research analysts have commented on NTLA shares. Royal Bank of Canada restated an "outperform" rating and issued a $54.00 target price on shares of Intellia Therapeutics in a research note on Thursday, September 19th. Stifel Nicolaus lowered their target price on Intellia Therapeutics from $80.00 to $64.00 and set a "buy" rating on the stock in a research note on Wednesday, September 11th. Cantor Fitzgerald restated an "overweight" rating and issued a $65.00 target price on shares of Intellia Therapeutics in a research note on Monday, June 24th. Truist Financial reaffirmed a "buy" rating and issued a $120.00 price target on shares of Intellia Therapeutics in a research report on Monday, June 24th. Finally, JPMorgan Chase & Co. reduced their price target on Intellia Therapeutics from $61.00 to $55.00 and set an "overweight" rating for the company in a research report on Monday, August 12th. One equities research analyst has rated the stock with a sell rating, four have given a hold rating, ten have given a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat.com, the company has a consensus rating of "Moderate Buy" and a consensus target price of $61.77.

Insiders Place Their Bets

In other news, CAO Michael P. Dube sold 2,012 shares of the business's stock in a transaction that occurred on Wednesday, October 2nd. The stock was sold at an average price of $19.01, for a total transaction of $38,248.12. Following the completion of the sale, the chief accounting officer now owns 47,012 shares in the company, valued at $893,698.12. The trade was a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. Company insiders own 3.00% of the company's stock.

Intellia Therapeutics Company Profile

Intellia Therapeutics, Inc, a genome editing company, focuses on the development of curative therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; NTLA-2002 for the treatment of hereditary angioedema; and NTLA-3001 for alpha-1 antitrypsin deficiency associated lung disease.